BRIEF—Emergex buys assets to develop vaccine patches

British T cell specialist Emergex Vaccines has acquired the assets of California’s Zosano Pharma, for an undisclosed amount.

The Oxfordshire-based firm, which is working on fully synthetic CD8+ T cell adaptive vaccines, has bought intellectual property, license agreements, and manufacturing equipment.

This includes a proprietary microneedle array patch (MAP) drug delivery system, which Emergex has used in proof-of-concept studies, combined with its candidates.

Brian Pfister, VP at Emergex’ US business, said the MAP technology was “an exceptional strategic fit that complements our CD8+ T cell adaptive vaccine platform.”

He added: “We look forward to future clinical study with our vaccine coated patches.”